We found that inhibitors targeting the same PI3K/mTOR pathway sensitize everolimus resistant breast cancer cell lines to growth inhibition (Fig 5), regardless of whether they are dual PI3K/mTOR kinase inhibitors (BEZ235 and GSK2126458) or an mTOR kinase specific inhibitor (AZD8055). Here, PIK3CA is linked to breast carcinoma.